ESMO TAT, known as “The Home of Phase I in Oncology”, is the leading congress focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development.

This congress will be dedicated to improving the conduct of early anti-cancer clinical trials, bringing together those who are developing the most promising new cancer drugs and unveiling exciting new data.